Simultaneous introduction of two recombinant plasmid constructs into cultured cells for the purpose of gene overexpression or promoter activity studies has long been achieved. Despite ample success achieved in cotransfection of a wide range of mammalian cell types, success in the second transfection of an already once transfected cell population, in particular endothelial cells (ECs), remains a major technical challenge. The mechanisms responsible for this second or subsequent transfection of what is termed "inefficiency of temporal transfection" might be similar to superinfection immunity, a phenomenon that can occur in the life cycles of both bacterial and mammalian viruses (2) . In this study, we attempted to improve the efficiency of temporal transfection using mammalian expression vectors bearing genes of interest under their retroviral LTR or cytomegalovirus (CMV) promoters, two commonly used promoters in gene expression studies. We performed our studies in a cultured endothelial cell line derived from bovine heart postcapillary venules (10) .
Initially, we tested the targeted ECs for efficient transfections using four different transfection methods that used calcium phosphate, DEAE-Dextran or two different commercial lipid-mediated transfection reagents with no success (data not shown). After measuring several parameters, such as transfection reproducibility and degree of cellular toxicity and convenience, we chose to continue our studies with TransIT transfection reagents (PanVera, Madison, WI, USA), one of the three commercially available cationic liposomes that were used in our initial gene transfer optimization trials. Briefly, all three TransIT ® polyamine transfection reagents (LT-1, LT-2 and LT-100) (1) belong to second-generation cationic liposome formulations and in particular demonstrated both enhanced transfection efficiency and minimal cellular toxicity in our sensitive microvascular endothelial cells. TransIT reagents are a variety of cationic lipids with amines that have pKs within the physiologic range of 4.5-8. Acidic conditions facilitate DNA binding and the delivery of functional DNA into cells by these cationic, pH-sensitive liposomes (1) .
Briefly, the ORF of human FGF-1 was cloned into the retroviral-based mammalian expression vector, pMEXneo, containing the MSV-LTR and an SV40 polyadenylation site and was used for stable transfection of microvascular ECs (4, 5, 8) . In addition, PCR was used to add a Kozak sequence (CCACCA -TGG) to the final construct for maximal eukaryotic translational efficiency (7) .
ECs isolated from 15-µ m diameter postcapillary venules of the bovine heart (10) were grown in DMEM (Life Technologies, Rockville, MD, USA) containing high glucose and L-glutamine supplemented with 10% (v/v) FBS (HyClone Laboratories, Logan, UT, USA), 100 U/mL penicillin G and 100 µ g/mL streptomycin (Life Technologies). The authenticity of our stably transfected endothelial cells was demonstrated by their unique ability to take up acetylated low-density lipoprotein (LDL) (data not shown). Plasmids were amplified in E. coli and purified using QIAGEN ® MaxiPrep ® kits (Qiagen, Valencia, CA, USA). For stable transfections, approximately 24 h before transfection, ECs were seeded at 2 × 10 5 cells/9.6 cm 2 surface area of each well of a 6-well tissue culture plate in DMEM/10% FBS so that they were about 80% confluent the next day. TransIT-LT1 polyamine transfection reagent was used for the delivery of the FGF-1 plasmid into the cells.
For DNA/polyamine complex formation, 6 µ L TransIT-LT1 was added dropwise into 100 µ L serum-free and antibiotic-free DMEM in a sterile plastic tube and left at room temperature for 5 min. Subsequently, 1.5 µ g plasmid DNA were added to the diluted TransIT, and the incubation continued for additional 5 min at room temperature. Next, the media were removed from the wells, and cells were washed with PBS. The mixture of the DNA/polyamine complex was added to cells, and incubation continued at 37°C with 5% CO 2 for 5 h. Media were then replaced with fresh DMEM/10% FBS overnight. The transfected cells were trypsinized and passaged at a 1:10 ratio in selection media made of DMEM/10% FBS and 800 µ g/mL G-418 ® (Life Technologies). The selection medium was changed three times weekly, and after 7-10 days, colonies of G-418-resistant cells were recovered with cloning cylinders and grown separately to confluence. After several passages, Western blot analysis was performed on total protein extracts from these cells to confirm FGF-1 overexpression (Figure 1 ). These stably transfected cells were subsequently subjected to a second round of transfection with a reporter plasmid consisting of nucleotides -361 to +157 of the human c-fos promoter fused to the pA3-luciferase reporter (12) . For the second transfection, untransfected or FGF-1/pMEXneo-transfected ECs were plated at 50 000 cells/well (25 000 cells/cm 2 ) in a 24-well plate in DMEM/10% FBS overnight at 37°C in a 5% CO 2 incubator. The next day, TransIT-LT2 was used for the delivery of the reporter constructs c-fos/luciferase and CMV promoter-driven β -galactosidase (CMV-β -gal; Stratagene, La Jolla, CA, USA) into stably transfected ECs. Transfection was performed as described above but with 0.5 µ g each reporter plasmid DNA and 6 µ L LT-2 per well. Media were removed and fresh DMEM/10% FBS was added to each well. After overnight incubation at 37°C, the retransfected ECs were washed with PBS and incubated in serum-free DMEM (BTS medium) (6) for 48 h. Subsequently, wells were treated for 18 h with serum-free medium or DMEM/10% FBS. The 10% FBS served as a positive control for induction of c-fos/luciferase activity in transfected cells because the c-fos promoter is inducible by the growth factors present in the exogenously added serum. After the incubation, media were aspirated and cells were lysed in 100 µ L luciferase lysis buffer/well (BD PharMingen, San Diego, CA, USA). Aliquots of cell lysates (10 µ L) were assayed for luciferase activity using a commercially available kit (BD Pharmingen) and measured on a TopCount ™ Microplate Scintillation and Luminescence Counter (Packard Industries, Downer's Grove, IL, USA). β -gal activity (20 µ L cell lysate) was measured colorimetrically at 575 nm on a microplate reader using chlorophenol red β -D -galactopyranoside substrate (3). Luciferase activity was normalized to β -gal activity to correct for differences in transfection efficiency between different samples (Figure 2 demonstrate that these temporally transfected cells co-express different transgenes. Briefly, pMEXneo vector alone or FGF-1/pMEXneo-stably transfected ECs were plated in 24-well plates and transiently transfected with CMV-β -gal as described above. After 72 h, wells were fixed with 0.5% glutaraldehyde in PBS for 10 min and then stained with X-Gal solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 and 1 mg/mL X-Gal) until sufficient blue color developed to indicate transfected endothelial cells. Wells were subsequently washed with TBS, pH 7.5, treated with methanol for 15 min, permeabilized with 0.1% Triton ® X-100 in TBS for 10 min, rinsed again with TBS and incubated for 1 h with blocking buffer (2.5% BSA/0.05% Tween ® 20 in TBS (Figure 3) . We report here a method that we developed to successfully introduce functionally different genes into ECs in a temporal manner. Furthermore, we established a coordinated interaction between the two overexpressed genes by demonstrating an increase in the promoter activity of the secondary (cfos/luciferase) in response to the primary (FGF-1) overexpressed genes. While methods for simultaneous co-transfection of plasmids have been established, the second transfection of a stably transfected cell population has proven to be technically challenging. Attempts have only been successful to temporally transfect and retransfect some cells of non-endothelial origins (9, 11) . A major advantage of the described temporal transfection is that it would allow for the primary stably overexpressed gene to generate new phenotype(s) over a period of time in a culture dish. Using subsequent rounds of transfections for many more individual genes, it would be possible to define molecular switches responsible for those newly formed phenotype(s). In our system, we have been able to perform tertiary transfection of EC using the CMV-β -gal reporter plasmid as an internal control for 
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the efficiency of transfection. In light of the fact that ECs are difficult to transfect, the success of this method is warranted for a wider range of cells with different origins. In fact, we have obtained similar results in temporally transfecting NIH 3T3 cells using this method (data not shown). In addition, this method of temporal transfection might have utility in reversing cellular abnormalities through genetic intervention of the temporally introduced gene.
